Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV)

NCT01756482 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

DRUG: GS-5806
DRUG: Placebo

Sponsor

Gilead Sciences